neurodegenerative disease

ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.

The funding will support development of tests that detect cell-free DNA methylation patterns indicative of disease in specific tissues of the body.

The RNA products developer is buying California-based Narus in order to expand into the RNA-based diagnostics market.

The companies will evaluate Diamir's technology as a potential companion diagnostic to certain Janssen neurodegenerative disease programs.

UK-based XRGenomics is using Affymetrix's GeneTitan platform to develop a gene expression signature as a stratification tool for dementia research.

The San Francisco-based startup looks to apply its algorithms to gene networks implicated in neurodegenerative diseases to find drug targets.

DioGenix and its MSPrecise NGS test for multiple sclerosis will be merged into Amarantus as a foundational asset of a growing neuro-diagnostic business.